FDA Approves Additional Application for Mercadon Gardasil 9: Can Be Used for Vaccinations in Adult sand and men aged 27-45

recently,supplements application from the FDA(approved for the Mercadon Gardasil 9 (9-price recombinant HUMAN papillomavirus vaccine, HPV vaccine) for use in adults aged 27-45Prior to, Gardasil 9 was available to female or male adolescents and adults aged 9-26, and the FDA did not approve any HPV vaccine for people over the age of 26gardasilGardasil (4-price HPV vaccine) was first approved by the FDA in June 2006In December 2014, the FDA approved Mercadon Gardasil 9 to prevent cervical, vulva, vaginal and cancers caused by HPV16, 18, 31, 33, 45, 52 and 58, as well as genital warts caused by HPV6 and type 11In addition to covering the four virus strains that Gardasil can be immune to, Gardasil 9 has added five more strainsGardasil is also increasingly haltingsupplyin the U.SmarketIn 2016, GSK's 2-price HPV vaccine, Cervarix, a bivalent human papillomavirus adsorption vaccine, also withdrew from the U.SmarketGardasil 9 covers four strains of the gardasil virus and uses a production process similar to That's, which the FDA considers comparableIn a large clinical trial of 3,200 women aged 27 to 45 with an average follow-up of 3.5 years (in which Gardasil was effective at the compound endpoint of preventing HPV infection, sharp warts, pre-vaginal lesions, pre-cervical cancer, HPV infection-related cervical cancer, etc.), was 88% 　　The FDA's approval of Gardasil 9 for 27-45 year olds is also based on the findings and the study's longer follow-up data 　　The safety of Gardasil 9 was assessed in 13,000 women and men, and common adverse reactions included pain, swelling and redness at the injection site, as well as headaches